Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ 100 Technology Index Fund vs Recursion Pharmaceuticals Inc — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $310.91, while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QTEC | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $335.74 | $6.79 |
52-Week Low | $207.03 | $2.84 |
Market Cap | — | $1.86B |
Enterprise Value | — | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QTEC trades at $311.57, down 0.22% with neutral technical signals. The ETF shows bearish moving averages but neutral oscillators, with key support at $310 and resistance at $313. Recent coverage highlights its equal-weighted tech exposure and liquidity advantages over peers like RSPT, with software appearing undervalued relative to historical averages according to Seeking Alpha analysis.
The technology sector ETF offers diversified exposure but faces typical sector volatility risks. Current technical positioning suggests limited near-term momentum, while fundamental analysis indicates selective value opportunities within the portfolio components. Market sentiment remains balanced between growth potential and valuation concerns in the tech space.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
